In an October 7, 2009 press release, Quest Diagnostics, Inc now offers a saliva-based rapid PCR screen for the cytochrome oxidase P450 2C19 polymorphisms CYP2C19*2, *3, *4 and *5 associated with clopidogrel dosage variation, AKA “clopidogrel resistance.” The test may be used to screen patients prior to clopidogrel therapy in an effort to establish the correct dosage or to switch to alternative anti-platelet therapy. It is the first saliva-based PCR available for clinical testing.
Shuldiner AR, C’Connell JR, Bilden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama 2009;302: 849–57.
Bhatt DL. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA 2009;302: 896–7.
No comments here.